March 30th, 2014
MADIT-CRT Long-Term Follow-Up Shows Survival Benefit with CRT-D
Larry Husten, PHD
MADIT-CRT was an influential trial that showed a reduction in heart failure complications — but not mortality — when cardiac resynchronization therapy (CRT) was added to an implantable defibrillator in patients with mild heart failure who also had left bundle-branch block (LBBB). Patients in the trial were followed for 2.4 years, raising questions about the long-term effects […]
March 25th, 2011
FDA Approves 2 New Cardiac Resynchronization Therapy-Pacemaker Systems From Medtronic
Larry Husten, PHD
The FDA has approved two new cardiac resynchronization therapy-pacemaker (CRT-P) systems manufactured by Medtronic, the company announced. Both the Consulta® and Syncra™ CRT-P systems include an ECG reporting system, which works with the company’s network data monitoring system to offer remote follow-up of heart-failure patients. In addition, the Consulta includes Medtronic’s fluid monitoring system and […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?